In a week with around 30% of the ASX200 reporting, we take a look at some of the best performers of the year so far and give you the context of where they are, where they are valued and what to focus on
Telix’s stock has been pummeled after announcing an SEC inquiry— a routine regulatory request, followed by a routine opportunistic law firm “investigation” are simply the cost of success in a high-profile sector, not a red flag
In this week’s episode of Bulls vs Bears from MPC Markets, the Mark & Jonathan dive into recent market highlights, commodity trends, stock picks, and geopolitical impacts on trading. They share insights from media appearances, discuss Trump-era tariffs, and provide a bullish outlook for the coming week amid US earnings season. Key focuses include copper, silver, Tesla, and emerging AI influences in markets.
Stocks closed slightly lower after clawing back losses late into the close as investors weighed reports of shake up at the Federal Reserve and ongoing strength in tech stocks.
When biotech headlines scream “SEC subpoena,” panic can quickly outweigh perspective. But beneath the sell-off frenzy surrounding Telix Pharmaceuticals’ recent regulatory disclosure lies a compelling opportunity masked by fear.
Telix’s stock has been pummeled after announcing an SEC inquiry— a routine regulatory request, followed by a routine opportunistic law firm “investigation” are simply the cost of success in a high-profile sector, not a red flag
Anticipating next week’s company earnings and economic figures.
Stay informed on the latest financial updates and trends with MPC Markets
Anticipating next week’s company earnings and economic figures.
Stay informed on the latest financial updates and trends with MPC Markets
Stocks floated higher overnight as Trump/Apple announcement fuelled a tech rally and investors cheered mostly bullish quarterly results.
Stocks most momentum from Mondays rebound after data showing services activity unexpectedly contracted stoked concerns about the underlying of the economy just as the quarterly earnings season continues.
As of August 5, 2025 (mid-morning AEST), Telix Pharmaceuticals (TLX) is trading around A$16.84–16.75, down approximately 17% from its previous close of A$20.24. This sharp intraday decline aligns closely with your noted price of $17 (assuming AUD). Below, I’ll address the reasons for this correction based on recent developments and why it still represents a strong buying opportunity to add to positions.
Stocks rebounded from Friday’s big sell off, as investors rushed to buy the dip on growing expectations for a rate cut.
Revenue is vanity. Profit can be misleading. Free cash flow doesn’t lie.
In this episode of Global Alpha Bulls versus Bears, Mark and Richard discuss the recent market trends, focusing on key earnings reports from major tech companies, the impact of AI and data center expansion, and the implications of economic indicators such as employment data